Patents Assigned to LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.
-
Patent number: 11773079Abstract: The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer.Type: GrantFiled: April 27, 2021Date of Patent: October 3, 2023Assignees: Chia Tai Tianqing Pharmaceutical Group Co, Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.Inventors: Ticong Huang, Huifeng Xiao, Rui Zhao, Fei Liu, Wei Wei, Hongjiang Xu, Xiaojin Wang, Jingli Wu
-
Publication number: 20230133735Abstract: The present invention relates to use of a pyrrolopyrimidine compound for treating hemophagocytic syndrome, and particularly relates to use of a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof for treating hemophagocytic syndrome.Type: ApplicationFiled: March 9, 2021Publication date: May 4, 2023Applicants: CHIA TAI TIANQING PHARMACEUTICAL CO. ,LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., SHOUYAO HOLDINGS (BEIJING) CO., LTD.Inventors: HONGMING LIANG, XIQUAN ZHANG, XUNQIANG WANG, DING YU, DONG WANG, Qi GE, ZHAO WANG, YINI WANG
-
Patent number: 11254665Abstract: The present application relates to a crystalline sulfamide compound, and in particular relates to a crystalline (S)—N—((S)-1-(2-chlorphenyl)-2-((3,3-difluorocyclobutyl)amido)-2oxoethyl)-2-(4-cyanopyridin-2-base)-N-(3-fluorophenyl)-isothiazolidine-3-formamide 1,1-dioxide, and a preparation method therefor, a crystalline composition, a pharmaceutical composition and uses thereof. An X-ray powder diffraction spectrum of a crystalline hydrate of formula II of the present application has diffraction peaks at positions of about 14.40°, 20.28°, 20.94°, 22.02°, and 24.46°, represented by 2?. The crystalline hydrate of formula II of the present application has good IDH1 inhibitory activity and performs high stability, and therefore has advantages in physical property, safety and metabolic stability, and has high medicine value.Type: GrantFiled: September 21, 2018Date of Patent: February 22, 2022Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., CENTAURUS BIOPHARMA CO., LTD.Inventors: Xiquan Zhang, Wenwei Xu, Mingming Li, Minmin Kong, Shufeng Wu, Aiming Zhang
-
Patent number: 11203586Abstract: An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer.Type: GrantFiled: March 22, 2017Date of Patent: December 21, 2021Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.Inventors: Li Zhu, Yanqing Yang, Liguang Dai, Xiaowei Duan, Zhao Yang, Hui Zhang, Yuandong Hu, Yong Peng, Yongxin Han, Rui Zhao, Xin Tian, Shanchun Wang
-
Publication number: 20210275534Abstract: A solid pharmaceutical composition containing a 1,3,5-triazine derivative or a pharmaceutically acceptable salt thereof and a preparation method therefor. In particular, involved are a solid pharmaceutical composition containing 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazine-2-amine or a pharmaceutically acceptable salt thereof and a preparation method therefor. The solid pharmaceutical composition has a good stability, a fast dissolution rate and a high bioavailability, and is suitable for clinical production and use.Type: ApplicationFiled: September 3, 2019Publication date: September 9, 2021Applicants: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., CENTAURUS BIOPHARMA CO., LTD.Inventors: Yuanyuan SUN, Shan ZHOU, Lei LIU, Ping DONG, Jing GAO, Laicun LI, Zhilin CHEN, Yi XU, Shang WANG
-
Patent number: 11111240Abstract: Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.Type: GrantFiled: March 22, 2017Date of Patent: September 7, 2021Assignees: Chai Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.Inventors: Li Zhu, Xiaowei Duan, Liguang Dai, Zhao Yang, Yanqing Yang, Hui Zhang, Yuandong Hu, Yong Peng, Yongxin Han, Rui Zhao, Xin Tian, Shanchun Wang
-
Patent number: 11098060Abstract: The present application relates to a macrocycle containing aminopyrazole and pyrimidine, which is represented by formula (I), a pharmaceutical composition thereof, and a use thereof in inhibiting tropomyosin receptor kinase (Trk) activity and in treating diseases in mammals that are mediated by Trk.Type: GrantFiled: August 23, 2018Date of Patent: August 24, 2021Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., CENTAURUS BIOPHARMA CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.Inventors: Liguang Dai, Xiaowei Duan, Yanqing Yang, Xijie Liu, Hongjuan Li, Na Zhao, Yinghui Sun, Fansheng Kong, Jiuqing Zhang, Yizhong Zhu, Ling Yang, Fei Liu
-
Patent number: 11021464Abstract: The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer.Type: GrantFiled: January 22, 2018Date of Patent: June 1, 2021Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd, Centaurus Biopharma Co., LtdInventors: Ticong Huang, Huifeng Xiao, Rui Zhao, Fei Liu, Wei Wei, Hongjiang Xu, Xiaojin Wang, Jingli Wu
-
Patent number: 10858340Abstract: Disclosed are a crystal of a maleate of a compound of formula (I), a preparation method for the crystal, a crystallization composition of same, a pharmaceutical composition of same, and uses thereof in preventing and treating a tumor.Type: GrantFiled: August 24, 2017Date of Patent: December 8, 2020Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO. LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., CENTAURUS BIOPHARMA CO., LTD.Inventors: Song Tang, Yizhong Zhu, Fei Liu, Jie Zhou, Zhilin Chen, Hongjiang Xu, Xin Tian
-
Patent number: 10829492Abstract: Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.Type: GrantFiled: October 27, 2017Date of Patent: November 10, 2020Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., CENTAURUS BIOPHARMA CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.Inventors: Li Zhu, Yuandong Hu, Wei Wu, Liguang Dai, Xiaowei Duan, Yanqing Yang, Yinghui Sun, Yongxin Han, Yong Peng, Fansheng Kong, Hong Luo, Ling Yang, Hongjiang Xu, Meng Guo, Zhaobai Zhong, Shanchun Wang
-
Patent number: 10822319Abstract: The present application relates to a crystal of a compound represented by Formula (I), a salt thereof, and a crystal of the salt thereof, a method for preparing the crystal of the compound represented by Formula (I), the salt thereof, and the crystal of the salt thereof, a crystal comprising the compound represented by Formula (I), a crystal composition comprising the crystal of the salt thereof, a pharmaceutical composition thereof, and medical uses thereof.Type: GrantFiled: August 11, 2017Date of Patent: November 3, 2020Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., CENTAURUS BIOPHARMA CO., LTD.Inventors: Guangming Sang, Lin Liu, Aiming Zhang, Jiabin Qiao, Xiaopeng Guo, Xiquan Zhang, Chunguang Xia
-
Publication number: 20200291012Abstract: The present application relates to a crystalline sulfamide compound, and in particular relates to a crystalline (S)-N-((S)-1-(2-chlorphenyl)-2-((3,3-difluorocyclobutyl)amido)-2oxoethyl)-2-(4-cyanopyridin-2-base)-N-(3-fluorophenyl)-isothiazolidine-3-formamide 1,1-dioxide, and a preparation method therefor, a crystalline composition, a pharmaceutical composition and uses thereof. An X-ray powder diffraction spectrum of a crystalline hydrate of formula II of the present application has diffraction peaks at positions of about 14.40°, 20.28°, 20.94°, 22.02°, and 24.46°, represented by 2?. The crystalline hydrate of formula II of the present application has good IDH1 inhibitory activity and performs high stability, and therefore has advantages in physical property, safety and metabolic stability, and has high medicine value.Type: ApplicationFiled: September 21, 2018Publication date: September 17, 2020Applicants: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., CENTAURUS BIOPHARMA CO., LTD.Inventors: Xiquan ZHANG, Wenwei XU, Mingming LI, Minmin KONG, Shufeng WU, Aiming ZHANG
-
Patent number: 10766901Abstract: Provided are a preparation method for a chiral pyrrolopyrimidine compound and a related intermediate. In the method, a compound of formula A and a compound of formula 6 or a salt thereof are reacted to obtain a compound of formula 7 or a compound of formula 14, and a compound of formula I is prepared from the compound of formula 7 or the compound of formula 14. Also provided are the intermediate used, a preparation method for the intermediate and a use of the intermediate in the preparation of the compound of formula I. The preparation method has characteristics such as brief steps, a high stereoselectivity, a high utilization ratio of atoms, mild reaction conditions and a convenient post-treatment. The method avoids using an expensive asymmetric reaction catalyst, and is suitable for industrial production.Type: GrantFiled: June 15, 2017Date of Patent: September 8, 2020Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., CENTAURUS BIOPHARMA CO., LTD.Inventors: Xiquan Zhang, Aiming Zhang, Zhou Zhou, Huadong Yao, Jie Xie
-
Patent number: 10745383Abstract: Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.Type: GrantFiled: July 29, 2016Date of Patent: August 18, 2020Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.Inventors: Na Zhao, Shulong Wang, Xijie Liu, Yuandong Hu, Hui Zhang, Hong Luo, Yong Peng, Yongxin Han, Xiquan Zhang, Hongjiang Xu
-
Patent number: 10654826Abstract: Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.Type: GrantFiled: July 29, 2016Date of Patent: May 19, 2020Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.Inventors: Na Zhao, Shulong Wang, Xijie Liu, Yuandong Hu, Hui Zhang, Hong Luo, Yong Peng, Yongxin Han, Xiquan Zhang, Hongjiang Xu
-
Patent number: 10626118Abstract: The present application relates to the field of pharmaceutical chemistry. The application specifically relates to a crystal form A and crystal form B of a pyrrolopyrimidine (formula I) for preparing a JAK inhibitor. The application further relates to a method for preparing the crystal form A and crystal form B, a crystalline composition comprising the crystal form A or crystal form B, a pharmaceutical composition comprising the crystal form A, crystal form B, or crystalline composition, and a pharmaceutical application of the pharmaceutical composition, the crystal form A, and the crystal form B. The crystal form A and crystal form B of the application has the advantages of high purity, high crystallinity, and good stability.Type: GrantFiled: June 15, 2017Date of Patent: April 21, 2020Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., CENTAURUS BIOPHARMA CO., LTD.Inventors: Zhou Zhou, Aiming Zhang, Xiquan Zhang, Huadong Yao
-
Patent number: 10617692Abstract: A pyrrolopyrimidine comprising a cyclopentyi substituent. The present invention specifically relates to a compound represented by formula. A and a stereoisomer and pharmaceutically acceptable salt thereof. The invention further relates to a method for manufacturing the pyrrolopyrimidine comprising the cyclopentyl substituent represented by formula A, a pharmaceutical composition, and an application of the compound in treating a disease induced by Janus kinase.Type: GrantFiled: June 15, 2017Date of Patent: April 14, 2020Assignees: CENTAURUS BIOPHARMA CO., CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.Inventors: Li Zhu, Yangjian Liu, Chuanyu Zhang, He Wang, Hong Luo, Yinghui Sun, Yongxin Han
-
Patent number: 10570141Abstract: The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.Type: GrantFiled: March 27, 2017Date of Patent: February 25, 2020Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., CENTAURUS BIOPHARMA CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.Inventors: Shulong Wang, Kuncheng Chen, Xijie Liu, Yuandong Hu, Bo Liu, Yong Peng, Hong Luo, Yongxin Han, Shanchun Wang, Mei Liu, Hongjiang Xu
-
Patent number: 10561657Abstract: The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase.Type: GrantFiled: December 15, 2015Date of Patent: February 18, 2020Assignees: Centaurus Biophrama Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd.Inventors: Li Zhu, Dengming Xiao, Yuandong Hu, Liguang Dai, Xiaowei Duan, Yinghui Sun, Yong Peng, Fansheng Kong, Hong Luo, Yongxin Han, Ling Yang, Shanchun Wang
-
Patent number: 10385038Abstract: The present invention discloses a crystal of citrate salt of pyridine-substituted 2-aminopyridine-based protein kinase inhibitors, in particular, to crystal of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4?-methoxy-6?-((S)-2-methylpiperazin-1-yl)-3,3?-bipyridin-6-amine citrate salt, a method for preparation thereof, a crystalline composition and a pharmaceutical composition comprising the crystal, and further discloses the use of crystals of citrate salt of the compound of Formula I in protein kinase-related diseases. The crystals of citrate salt according to the present invention are superior to 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4?-methoxy-6?-((S)-2-methylpiperazin-1-yl)-3,3?-bipyridin-6-amine or other salts of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4?-methoxy-6?-((S)-2-methylpiperazin-1-yl)-3,3?-bipyridin-6-amine in at least one aspect of bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, and the like.Type: GrantFiled: July 29, 2016Date of Patent: August 20, 2019Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., CENTAURUS BIOPHARMA CO., LTD.Inventors: Feng Gong, Xinlu Li, Rui Zhao, Xiquan Zhang, Xinhe Xu, Xijie Liu, Dengming Xiao, Yongxin Han